Supplies Pain Points — Slow Enrollment

When enrollment slows across multiple clinical studies, even the most meticulously planned drug supply can end up sitting idle in inventory, gradually approaching expiration while patient recruitment lags behind projections. This creates a precarious situation: should you trigger emergency production to keep the trial on schedule, or risk wasting valuable inventory?

Without real-time visibility into enrollment rates, site performance, and supply levels, it becomes nearly impossible to proactively manage risk and optimize your trials. Delays, inefficiencies, and unnecessary costs become almost inevitable.